Aytu Biopharma (AYTU) Gross Profit (2014 - 2026)

Aytu Biopharma (AYTU) has 13 years of Gross Profit data on file, last reported at $7.6 million in Q1 2026.

• Gross Profit for Q1 2026 came in at $7.6 million, down 40.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $36.7 million (down 21.37% YoY), and the FY2025 annual result was $45.8 million, down 6.57% from the prior year.
• Gross Profit eased to $7.6 million in Q1 2026 per AYTU's latest filing, from $9.6 million in the prior quarter.
• Over five years, Gross Profit peaked at $18.6 million in Q2 2023 and troughed at $7.6 million in Q1 2026.
• A 5-year average of $12.7 million and a median of $12.7 million in 2022 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2022 and 2026: Gross Profit surged 44.77% in 2022, then sank 40.66% in 2026.
• A 5-year view of Gross Profit shows it stood at $17.3 million in 2022, then dropped by 15.56% to $14.6 million in 2023, then declined by 26.14% to $10.8 million in 2024, then declined by 10.77% to $9.6 million in 2025, then decreased by 21.04% to $7.6 million in 2026.
• Business Quant data shows AYTU's Gross Profit at $7.6 million in Q1 2026, $9.6 million in Q4 2025, and $9.2 million in Q3 2025.